Beschreibung:
<jats:title>Abstract</jats:title><jats:p>The <jats:italic>in vivo</jats:italic> efficacy of human recombinant soluble tumor necrosis factor (TNF) receptor protein to prevent and to treat lipopolysaccharide (LPS)‐induced lethal toxicity in D‐galactosamine‐treated mice was investigated. Chimeric proteins of the receptor extracellular domains fused to the hinge region of human IgG3 were expressed in myeloma cells (rsTNFR‐hγ3). The fusion proteins had a disulfide‐bonded dimeric structure. Upon intravenous injection, their serum concentration decreased relatively slowly after an initial phase of rapid elimination. D‐galactosamine‐sensitized mice were fully protected from the toxic effects of LPS, if the animal were pretreated with rsTNFR‐hγ3 at 20 μg/animal. Partial protection was seen at significantly lower doses and when rsTNFR‐hγ3 was given up to 3 h after LPS.</jats:p>